Data from pharmawand - Curated by Toby Galbraith - Date added 25 July 2013

An advisory panel to the FDA voted against approving Humira ( (adalimumab) from AbbVie, for treating an inflammatory disease of the spine. The panel of independent advisors called for additional trials to prove the efficacy of the drug in treating early-stages of Spondyloarthritis.

The FDA will take the panel's 12 to 1 vote into consideration while deciding upon the final approval for this new use for the drug.


You will need to login, to leave a comment.

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.


Epidemiology, pathophysiology, diagnosis/treatment guidelines, recent publication summaries and more

Visit Hypogonadism

Type 2 Diabetes

View the latest epidemiology data, patient perspectives, ADA and EASD recommendations, treatment options and more

Visit Type 2 Diabetes

Related Content